Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

TIL Immunotherapy Drastically Increases the Number of Elite Cancer-Killing Lymphocytes in Your Body.

TIL Immunotherapy – Innovative Treatment to Fight Melanoma
Conventional cancer therapies are frequently ineffective against metastatic melanoma. TIL (tumor-infiltrating lymphocytes) immunotherapy is a highly progressive, promising treatment, with a high success rate.

TIL Immunotherapy – Innovative Treatment to Fight Melanoma

TILs, or tumor-infiltrating lymphocytes, are special immune system cells (T cells) that are naturally present inside some tumors. TIL therapy consists of collecting TILs from a tumor during a biopsy, or surgical resection, and growing them to very large numbers in a laboratory with interleukin-2 (IL-2), a protein that promotes rapid TIL growth. Once successfully grown to billions in number, the TILs are infused back into the patient, where they actively attack cancer cells while leaving healthy cells alone. After administering TIL immunotherapy, the size of the metastasis is often quickly reduced. This treatment is at the forefront of cancer therapies around the world, and it’s only offered by a few medical institutions. Sheba Medical Center performs TIL immunotherapy for metastatic melanoma for over 17 years.

TIL Immunotherapy – Innovative Treatment to Fight Melanoma

Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More
Hemophilia research
News Sep 05.

New Sheba Study Indicates: Novel Treatment Sharply Reduces Bleed Rates Among Hemophilia Patients

Results indicate that a monthly treatment with Fitusiran significantly reduces bleed rates among both hemophilia A and B patients.
Read More